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Preeclampsia (PE) affects 2%-5% of pregnancies in developed countries and is a major cause of maternal and perinatal morbidity and mortality due to FGR and preterm deliveries. The pathogenesis of PE remains obscure due to its heterogeneous and multisystemic nature. Delivery of the placenta is the only known treatment at this time, suggesting that this is a placental disease. It is currently believed that abnormal placentation occurs early in pregnancy and that this leads to placental ischemia. Effective methods for the prevention of PE are still lacking, therefore early prediction could be benefi cial for appropriate antenatal surveillance and prevention of maternal and fetal complications. To date three groups of predictive factors have been assessedclinical, biophysical and biochemical factors.
Doppler assessment of uterine artery blood fl ow resistance may be used to screen for PE either in the fi rst or second trimesters. 1, 2 The ischemic placenta is thought to secrete soluble factors during the third trimester that in turn induce systemic endothelial dysfunction and the maternal syndrome of preeclampsia. 3 Some of the soluble factors that have been investigated for the possibility of predicting development of PE are PP13 4 , soluble fms-like tyrosine kinase-1 (sFlt-1), soluble endoglin (sEnd), and most recently, corin. Each of these proteins is involved in different pathophysiological path of preeclampsia development.
AIM
The aim of this study was to fi nd the mean maternal serum concentration of four proteins (corin, sFlt-1, soluble endoglin and PP13) in Bulgarian pregnant women and to investigate the correlation with uterine artery pulsatility index in the fi rst and second trimesters of pregnancy.
MATERIALS AND METHODS
This was a prospective case-control study of women who conceived and delivered between 2013 and 2015 in the Department of Obstetrics and Gynecology of St George University Hospital in Plovdiv, Bulgaria. More than 60 women participated, but only 40 met the including criteria for the trial. These women were divided in two groups of 20 women each. Group 1 was the experimental group with the women pregnant at their gestational weeks 11 to 13, with their mean uterine artery Doppler pulsatility index (mean PI) greater than 2.0. The women in group 2 (controls) had mean PI of both uterine arteries at weeks 11-13 less than 2.0.
Gestational age was calculated from the last menstrual period and confi rmed by crown-rump length (CRL) measurement at weeks 11 to 13. Screening for aneuploidies was performed at the same gestational age for all participating pregnant women and those with abnormal results were excluded from the trial. Maternal venous serum samples were collected from all women twice in their pregnancy-once in their fi rst visit at weeks 11 to 13 and the other time -at weeks 20 to 22, when US fetal morphology examination is performed.
In all cases, 5 mL of maternal blood was drawn into a nonheparinized tube, allowed to clot, and centrifuged. Maternal serum samples were stored at -80°C for up to 3 years until analysis in the laboratory in Department of Microbiology and Immunology, Faculty of Pharmacy, Medical UniversityPlovdiv, Bulgaria.
Ultrasound scan was performed as part of routine antenatal care, and uterine artery pulsatility index (PI-UA) was measured in the women that met the inclusion criteria again twice -fi rst at weeks 11 to 13 and the second time -at weeks 20 to 22. PI-UA was measured according to the accepted standards and was calculated automatically for both sidesthe right and left uterine arteries. Then the mean PI at both sides was calculated. Ultrasound scans were performed with GE Voluson E6 and only by the leading author after an appropriate training (the author obtained the Fetal Medicine Foundation Certifi cate of Competence in Doppler assessment of uterine).
Patient characteristics including BMI, smoking status, and obstetric and medical history were obtained from women at the fi rst visit.
Women with medical conditions known to contribute to a hypertensive disorder and preeclampsia risk profi le, including diabetes mellitus, connective tissue disease, renal disorders, and essential hypertension, were excluded from the study along with the women with multiple pregnancy. All women had a blood pressure less than 140/90 mm Hg and no history of hypertension when requesting maternity care. Pregnancy outcomes of interest were gestational age of delivery, way of delivery-vaginal or cesarean section, birth weight, onset of preeclampsia and/or fetal retardation.
Women with preeclampsia were diagnosed according to the guidelines of the International Society for the Study of Hypertension in Pregnancy.
Local research ethics committee approval was obtained for the study, and all participating women gave written informed consent.
All analyses of blood samples were performed in a blind fashion. Maternal serum concentrations of soluble endoglin (sEnd), corin, PP13 (pg/ml) and sFlt-1 (ng/ml) were measured in the experimental group and controls using ELISA in the University laboratory of Department of Microbiology and Immunology, Faculty of Pharmacy, Medical University -Plovdiv, Bulgaria.
Data were presented as mean ± SD or as a percentage. All numeric variables were tested for normal distribution by applying Kolmogorov-Smirnov test. Data were compared between the two groups using Pearson χ 2 tests and paired or unpaired Student's t tests for categorical traits and continuous traits, respectively. Correlations were evaluated using Pearson's correlation coeffi cient test. A two-tailed P value less than 0.05 was considered statistically significant. Repeated measures ANOVA with a Greenhouse-Geisser correction was used to compare group means where the participants are the same in each group.
RESULTS
A total of 40 patients were recruited allocated into two groups of 20 patients in the experimental group and in controls. Table 1 presents the clinical characteristics of both groups. No difference in examining parameters was noted between two groups.
All included pregnant women in the trial were non-smokers, with no history of previous PE or hypertension.
Women in the control and experimental groups were age, parity, and BMI matched ( Table 1) ; they had normal blood pressure. NT (nuchal translucency) of all fetuses was within normal range in the fi rst ultrasound examination. None of the controls developed PE, gestational hypertension or fetal retardation. Three women in the experimental group developed PE in mean week 35 (in the 37th, 32nd, and 35th week of gestation, respectively) and two women delivered fetuses with retardation (fetal weight below the 10th percentile for gestational age).
There was no signifi cant difference in the AP-GAR score, birth weight and height of the newborns between controls and the experimental group. Signifi cant difference was found in the systolic blood pressure between the two groups, when participating in the trial, but it was within the normal range (below 140 mmHg for systolic) in both groups.
We fi rst measured the mean concentrations of sEnd, corin, sFlt-1, and PP13 in maternal serum ( Table 2) . Each of these proteins involves a different pathophysiological path of PE development. We found no signifi cant differences in the mean concentrations of sEnd, sFlt-1 and PP13 between the 11th -13th weeks of gestation and the 20th gestational week for the controls and the experimental group. A statistically signifi cant difference was found only in the mean serum concentrations of corin between the 11th -13th weeks of gestation and Then we measured the mean PI of uterine arteries with Doppler ultrasound at 11 -13 weeks gestation and at 20 weeks gestation in both groups and checked if there was a statistical difference between the groups with the progression of pregnancy. In both groups, the mean PI of uterine arteries was found to decrease statistically signifi cantly with advancement of pregnancy: in the control group from 1.27±0.08 at weeks 11-13 of gestation to 0.97±0.06 in the 20th week of gestation (Z=-2.50; p=0.012); in the experimental group -from 2.13±0.08 at weeks 11-13 of gestation to 1.12±0.07 at week of gestation 20 (Z=-3.72; p=0.000). Our results are consistent with a previous fi nding that PI declines with advancing gestational age in line with increasing uteroplacental blood fl ow. 5 A repeated measures ANOVA with a GreenhouseGeisser correction determined that mean corin concentration (pg/ml) in the control group differed statistically signifi cantly between time points (the 13th and 20th weeks of gestation) -F(12541.37, 1.000)=10.716, p=0.004. Post hoc tests using the Bonferroni correction showed that mean corin concentration decreased signifi cantly from the 13th week of gestation to the 20th week of gestation (2656.14 ± 596.52 vs 2289.53 ± 308.51, mean±SD; p=0.004).
A repeated measures ANOVA with a GreenhouseGeisser correction determined that mean PP13, sFlt-1 and sEndoglin in controls did not differ statistically signifi cantly between time points (the 13th and 20th weeks of gestation) -F(2894.46, 1.000)=3.672, p=0.070; F(1.22, 1.000)=3.350, p=0.083 and F(12847868.33, 1.000)=0.075, p=0.787, respectively.
A repeated measures ANOVA with a GreenhouseGeisser correction determined that mean corin concentration (pg/ml) in the experimental group differed significantly between time points (the 13th and 20th gestational weeks) -F(392078.544, 1.000)=10.366, p=0.005. Post hoc tests using the Bonferroni correction revealed that mean corin concentration decreased statistically signifi cantly from week 13 to week 20 (3016.87±715.53 vs 2344.88±484.18, mean±SD; p=0.005).
A repeated measures ANOVA with a GreenhouseGeisser correction determined that mean PP13, sFlt-1 and sEndoglin in the experimental group did not differ statistically signifi cantly between the 13th and 20th weeks of gestation) -F(2627.087, 1.000)=1.146, p=0.299; F(1.113, 1.000)=0.482, p=0.497 and F(410250.268, 1.000)=0.460, p=0.507, respectively.
We allocated the women in the experimental group into 3 subgroups -women with preeclampsia (n=3), women with fetal retardation (n=2) and all the rest (n=15). The subgroup analyses (preeclampsia vs fetal retardation) showed no differences between mean concentrations of corin, PP13, sFlt-1, and sEndoglin at the 13th and the 20th weeks of gestation. A signifi cant difference was found in the mean corin concentration (week of gestation 13) between women that developed preeclampsia and subgroup 3 (no preeclampsia, no fetal retardation) -t=2.332, p=0.046. The corin levels were signifi cantly reduced in the preeclampsia subgroup (2590.62±307.22 vs. ANOVA showed non-signifi cant main effect of the subgroup type on corin concentration -F(1, 15)=1.269, p=0.145. In addition, Greenhouse-Geisser correction determined that the corin levels between the three subgroups in the experimental group did not differ statistically signifi cantly between time points (the 13th and 20th gestational weeks) -F(2627.087, 1.000)=1.146. No differences were found in corin levels between experimental and control group at the 13th week of gestation (t=1.68, p=0.103) and at the 20th gestational week (t=0.42, p=0.681).
3235.18±734.07, mean±SD). A repeated measures
A repeated measures ANOVA with a GreenhouseGeisser correction determined that mean PI scores in the control group differed statistically signifi cantly between time points (the 13th and 20th gestational weeks): F(0.102, 1.000)= 9.269, (p=0.007). Post hoc tests using the Bonferroni correction revealed that the mean value of PI decreased statistically signifi cantly from week 13 to week 20 of gestation (1.2745±0.35 vs 0.9678±0.27, mean±SD); p=0.007).
A repeated measures ANOVA with a GreenhouseGeisser correction determined that mean PI scores in experimental group differed statistically signifi cantly between time points (the 13th and 20th gestational weeks): F(0.083, 1.000)=110.186 (p=0.000). Post hoc tests using the Bonferroni correction revealed that the mean PI decreased signifi cantly from the 13th to the 20th weeks of gestation (2.1314±0.35 vs 1.1206±0.30, mean±SD), (p=0.000).
The results from the analysis of experimental and control group, using a repeated measures ANOVA with a Greenhouse-Geisser correction showed a statistically signifi cant difference in mean PI scores between time points (weeks 13 and 20) -F(0.093, 1.000)=88.434, p=0.000. There was a signifi cant main effect of the group type -F(1, 36)=25.25 (p=0.000). Based on the type of the group -experimental or control -we have a statistically signifi cant difference in the PI mean scores over time. We proved a signifi cant between-subjects effect F(1, 36)=44.58, p=0.000. This effect demonstrated that mean PI scores differed in experimental and control groups. Both mean PI scores -at week 13 and week 16 -were lower in controls than in the experimental group: 1.2747±0.35 vs 2.1314±0.35 (mean±SD); p=0.000 and 0.9678±0.27 vs 1.1206± .30 (mean±SD); p=0.000, respectively.
DISCUSSION
PE and FGR as major causes of perinatal and maternal morbidity and mortality are of high scientifi c interest. In normal pregnancy the blood fl ow in the uterine arteries decreases with gestation, and histopathological studies suggest that this is due to trophoblastic invasion of the spiral arteries. Failure of trophoblastic invasion is associated with complications of uteroplacental insuffi ciency. Several Doppler screening studies, both in the second and more recently in the fi rst trimester of pregnancy, have demonstrated an association between increased impedance to fl ow in the uterine arteries and subsequent development of pre-eclampsia and FGR. 1 Several angiogenic, anti-angiogenic, infl ammatory, clinical (mean arterial pressure) and biophysical (uterine artery Doppler) biomarkers, alone and in combination, have been proposed for prediction, but limited predictive values have hindered their clinical use. We hypothesized that the combination of biophysical (Doppler) and biochemical factors will be more effective in predicting preeclampsia. Our fi rst data failed to prove this hypothesis.
The only biochemical factor that has been changed in our investigation is corin. Corin is a transmembrane cardiac protease involved in sodium homeostasis and blood pressure regulation. Given its important role in blood pressure regulation, levels of soluble corin are reduced in patients with heart failure. 6 Corin defi ciency has been linked to high blood pressure. Expression of corin was detected in the decidua of pregnant uteri, indicating a role in trophoblast invasion and uterine spiral artery remodeling. 7 Cui Y et al. have identifi ed corin gene mutations in pre-eclamptic patients, which decreased corin activity in processing pro-ANP. 8 These results indicate that corin and ANP are essential for physiological changes at the maternalfetal interface, suggesting that defects in corin and ANP function may contribute to pre-eclampsia. The data in the literature for plasma levels of corin in PE are sparse and controversial. Khalil et al. described the potential use of maternal plasma corin for early prediction of preterm PE. They observed signifi cantly lower levels of maternal plasma corin until 20 weeks of gestation in the preterm PE group compared with the normotensive group and concluded that maternal plasma levels of corin can potentially be used as an early predictor of preterm PE. 9 Contrary to this are the results of Miyazaki J et al. 6 , who found elevated serum corin levels in women with pre-eclampsia and also in unexplained fetal growth restriction (FGR) without hypertension. They also fi nd an increase of immunoreactivity of corin in the maternal decidua in pre-eclampsia and FGR without hypertension which might be the possible source of increased secretory corin. They also speculated that the other possible organ apart from uteroplacental bed is cardiac myocytes.
Plasma corin levels may not refl ect accurately the localized functional corin levels around uterine tissues, concluded Jadli A et al. and may, in fact, have only a minor role to play in predicting PE. By their opinion both uterine-tissue-specifi c and peripheral-circulation corin levels should be analyzed in large-scale studies, to assess its role as a sensitive and specifi c predictive biomarker for PE and other adverse pregnancy-related conditions. 10 Regardless of the confl icting results from different studies, evaluating the role of plasma corin in predicting PE, it appears to have potential as a marker for early prediction of PE. 11 A limitation of the study was the relatively small sample size. The small number of women who developed PE in the experimental group restrict our study to evaluate whether those markers could be used in a predictive model for PE. Further studies are needed to fi nd out whether soluble factors of placental origin could be used for prediction of PE in risk groups.
CONCLUSIONS
Further prospective studies of larger populations are required to develop a panel of multiple predictors for PE to cover all possible pathophysiologic mechanisms. 5 
